Transaction DateRecipientSharesTypePriceValue
5th January 2021Mark E Saad8,227Grant/award etc.$0.00
18th November 2020Roger Jeffs1,387,500Other acquisition or disposition$6.00$8,325,000.00
12th October 2020Mark E Saad100,000Grant/award etc.$0.00
19th August 2020Mark Coleman397,998Bona fide gift$0.00
19th August 2020Mark Coleman397,998Bona fide gift$0.00
29th June 2020Nick Pizzie777Open or private purchase$76.64$59,549.28
29th June 2020Mark Coleman650Open or private purchase$78.50$51,025.00
10th January 2020Roger Jeffs11,000Exercise of derivative$4.95$54,450.00
10th January 2020Roger Jeffs9,127Exercise of derivative$9.00$82,143.00
10th January 2020Roger Jeffs34,866Exercise of derivative$12.95$451,514.70
Axsome Therapeutics
Axsome Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company was founded by Herriot Tabuteau on January 12, 2012.

Ticker: AXSM
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1579428
Employees: 45
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Assets, Current: $191 M (-13%)
Property, Plant and Equipment, Net: $30 Th (0%)
Other Assets, Noncurrent: $140 Th (0%)
Assets: $191 M (-13%)
Long-term Debt, Current Maturities: $7 M (0%)
Accounts Payable, Current: $9 M (-14%)
Liabilities, Current: $23 M (-6%)
Long-term Debt, Excluding Current Maturities: $14 M (0%)
Liabilities: $37 M (-12%)
Common Stock, Value, Issued: $4 Th (0%)
Common Stock, Shares, Issued: $37 M (0%)
Retained Earnings (Accumulated Deficit): $227 M (0%)
Stockholders' Equity (Parent): $154 M (0%)
Liabilities and Equity: $191 M (-13%)
Research and Development: $11 M (-72%)
General and Administrative Expenses: $7 M (-40%)
Operating Income/Loss: $18 M (-64%)